Infectious DiseaseAs the 2026–2027 respiratory syncytial virus season approaches, parents now have more than one way to protect an infant from severe RSV, but the choices can be confusing. A September 2026 American Academy of Pediatrics policy update keeps the basic first-season strategy intact while expanding the group of high-risk children who should receive protection during […]
Read the Full Bite →
Clinical Research & TrialsNirsevimab is designed to cover an RSV season with one dose. Trials show protection for at least 5 months, with hospitalization protection through 180 days.
Read the Full Bite →
Clinical Research & TrialsBeyfortus dosing changes by weight and RSV season. Here is when nirsevimab is given as 50 mg, 100 mg, or 200 mg and who is eligible.
Read the Full Bite →
Infectious DiseaseNirsevimab and clesrovimab both prevent severe infant RSV disease, but they bind different viral sites, use different dosing schemes, and were not tested head to head.
Read the Full Bite →
Infectious DiseaseMaternal RSV vaccination and nirsevimab both protect infants from severe RSV, but they work differently and their trial efficacy numbers are not directly comparable.
Read the Full Bite →
Pediatrics & Child HealthTwo batches of infant formula were recalled. Here's how to check and what to do.
Read the Full Bite →